Navigation Links
Capricor Therapeutics to Present at Two Investor Conferences in March
Date:2/23/2017

LOS ANGELES, Feb. 23, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for cardiac and other medical conditions, today announced that Linda Marbán, Ph.D, president and chief executive officer, is scheduled to present at two upcoming investor conferences:

  • Cowen and Company 37th Annual Health Care Conference
    Tuesday, March 7, 2017 at 10:00 am ET
    Boston, MA
  • 29th Annual ROTH Conference
    Tuesday, March 14, 2017 at 9:00 am PT (12:00 pm ET)
    Dana Point, CA

Webcasts of both presentations will be available on Capricor's website at http://capricor.com/news/events/ and will be archived for approximately 30 days.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other medical conditions. Capricor's lead candidate, CAP-1002, is a cardiac cell therapy that is currently being evaluated for the treatment of heart disease associated with Duchenne muscular dystrophy and myocardial infarction (heart attack). Capricor is exploring the use of CAP-2003, its exosome product candidate, in various therapeutic areas including the treatment of ophthalmic disorders. For additional information, visit www.capricor.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, expectations with respect to the expected use of proceeds from the recently completed offering and the anticipated effects of the offerings, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business are set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission on March 30, 2016, in its Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on September 28, 2015, and in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, as filed with the Securities and Exchange Commission on November 14, 2016. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

CAP-1002 is an Investigational New Drug and is not approved for any indications. Capricor's exosomes technology, including CAP-2003, has not yet been approved for clinical investigation.

For more information, please contact:

Corporate
Capricor Therapeutics, Inc.
AJ Bergmann, Vice President of Finance
+1-310-358-3200
abergmann@capricor.com 

Investor Relations
Argot Partners
Kimberly Minarovich
+1-212-600-1902
kimberly@argotpartners.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/capricor-therapeutics-to-present-at-two-investor-conferences-in-march-300412356.html


'/>"/>
SOURCE Capricor Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Capricor Therapeutics Provides Update on Natriuretic Peptide Program
2. Capricor Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
3. Capricor Awarded $3.4 Million Grant from California Institute for Regenerative Medicine
4. Capricor Therapeutics Announces $4 Million Registered Direct Offering
5. Capricor Therapeutics to Present at Upcoming Investor Conferences
6. Capricor Therapeutics Appoints Leland J. Gershell, M.D., Ph.D. as Chief Financial Officer
7. Capricor Therapeutics to Present at 18th Annual BIO CEO & Investor Conference
8. Capricor Therapeutics to Present at the 2015 JMP Securities DMD Forum
9. Capricor Therapeutics to Present at the 2015 Piper Jaffray Healthcare Conference
10. BioLife Solutions Customer Capricor Therapeutics Provides Update on Heart Failure Cell Therapy Safety Data at American Heart Association Scientific Sessions
11. Capricor Therapeutics Presents Positive Data from the DYNAMIC Clinical Trial at 2015 American Heart Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2019)... ... , ... The technology at the heart of Nanopareil revolves around ... the pharmaceutical industry could be massive. , “The pharmaceutical industry really needs this technology,” ... Dakota School of Mines & Technology and one of the researchers to develop ...
(Date:11/20/2019)... ... November 20, 2019 , ... Defense and aerospace market intelligence ... generation units from 2019-2028. The value of this production is $728 million in ... worth $569 million. , Reference to 2017 is important, as that was ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... new Director of Forensic Genealogy, Melinde Lutz Byrne, to the organization. Byrne’s team ... ultimately provide investigative leads to law enforcement through proven genealogy and DNA analysis ...
(Date:11/5/2019)... SOMERSET, N.J. (PRWEB) , ... ... ... leading global provider of advanced delivery technologies, development, and manufacturing solutions for ... of its next-generation cell line development technology, GPEx® Boost. The technology enhances ...
Breaking Biology Technology:
(Date:11/19/2019)... ... November 19, 2019 , ... Project Lifeline – ... Stores (NACDS) Foundation to address substance use disorder (SUD) – will take ... who have led to the program’s effectiveness in preventing and treating opioid abuse in ...
(Date:11/14/2019)... ... 13, 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human ... approved clinical trial for stem cell treatment of knee osteoarthritis . The first treatment ... subsidiary of VetStem Biopharma. , In July of 2019, PSC received FDA approval ...
(Date:11/12/2019)... ... November 12, 2019 , ... Atlantic Ultraviolet ... announced today that distributors voted their patented automatic and manual wipers the #1 ... , The most frequent maintenance task required of an ultraviolet water purifier is ...
Breaking Biology News(10 mins):